CEL-SCI Corporation - Product Pipeline Review - 2013 - New Study Released

Global Market Direct's pharmaceuticals report, "CEL-SCI Corporation - Product Pipeline Review - 2013" provides data on the CEL-SCI Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, CEL-SCI Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from CEL-SCI Corporation and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- http://www.fastmr.com/prod/594963_celsci_corporation_product_pipeline_review_2013.aspx?afid=301

Scope

* CEL-SCI Corporation - Brief CEL-SCI Corporation overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of CEL-SCI Corporation human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of CEL-SCI Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the CEL-SCI Corporation's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Evaluate CEL-SCI Corporation's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of CEL-SCI Corporation in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the CEL-SCI Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with CEL-SCI Corporation.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of CEL-SCI Corporation and identify potential opportunities in those areas.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Elan Corporation, plc - Product Pipeline Review - 2013
- Yuhan Corporation - Product Pipeline Review - 2013
- Generex Biotechnology Corporation - Product Pipeline Review - 2013
- Green Cross Corporation - Product Pipeline Review - 2013
- United Therapeutics Corporation - Product Pipeline Review - 2013